Rectal Carcinoma Clinical Trial
— COLOREOfficial title:
Phase II Study of Up-front Chemotherapy and Neo-adjuvant Short-course Radiotherapy for Resectable Rectal Carcinoma
Verified date | June 2023 |
Source | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Phase II study of up-front chemotherapy and neo-adjuvant shortcourse radiotherapy for resectable rectal carcinoma. Study Design: Phase II, open-label, single-arm, multi-centre study. STUDY PRODUCT,DOSE,ROUTE,REGIMEN AND DURATION OF ADMINISTRATION: 1. Neoadjuvant Treatment (pre-operative chemo-radiotherapy regimen): FOLFOX4* 2 cycles (WK1+WK3) - Tomotherapy** (WK5) - FOLFOX4* 2 cycles (WK7+WK9) * Oxaliplatin 85 mg/m2 iv: day 1 Levofolinate 100 mg/m2 iv: day 1-2 5-fluorouracil 400 mg/m2 iv in bolus and 600 mg/m2 iv infusion over 22h: day 1-2 Every cycle will last 2 weeks (approximately 48 hours of treatment infusion and 12 days of rest). ** 25 Gy in 5 consecutive fractions, one fraction per day in 5 days on CTV (Clinical Target Volume) at the isodose of the 95% of the total dose. The treatment plan will be elaborated at the work-station dedicated to the Helicoidal Tomotherapy. The treatment could be planned also with linear accelerator with IGRT-IMRT technique or VMAT technique. 2. Restaging (week 11) 3. Surgery (week 12-16) with Total Mesorectal Excision (TME) 4. End Of Treatment (week 16-32) 5. Adjuvant therapy (The maximum interval between surgery and start of adjuvant therapy should be 8 weeks): 6. FOLFOX4* 8 cycles (every 2 weeks) Study Duration: about 5 years. Enrollment period: 36 months. Treatment period: about 8 months. Follow-up: 1 year. NUMBER OF SUBJECTs: · Step A: a maximum of 6 patients. 6 evaluable patients are needed to assess toxicity. If 1 toxicity resulting in discontinuation of treatment will be observed in 6 patients, the treatment can be considered safe (with a confidence > 90%). If 2 or more toxicity resulting in discontinuation of treatment on 6 patients, the study will be stopped because not safe and another type of radiotherapy schedule must be designed. · Step B: a total of 50 patients is required to be recruited in 2 years (including patients enrolled in Step A). The goal is to achieve a proportion of at least 15% of patients with a complete pathological response with the new radiochemotherapeutic treatment.
Status | Completed |
Enrollment | 52 |
Est. completion date | March 31, 2019 |
Est. primary completion date | March 31, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Patients with histologically or cytologically confirmed diagnosis of adenocarcinoma of the mid-low rectum (within 12 cm from the anal verge) 2. Stage: lowT2N0, T2N+M0, T3-4 N-/+M0 (N+ = = 3 nodes >0,5 cm diameter or = 1 nodes > 1 cm diameter) 3. Age =18 and = 80 years 4. ECOG performance status 0-1 5. Patients must have normal organ and marrow function as defined below: 1. - Leukocytes = 3,000/mL 2. - Absolute neutrophil count = 1,500/mL 3. - Platelets = 100,000/mL 4. - Total bilirubin = 1.5 X ULN 5. - AST (SGOT)/ALT (SGPT) = 2.5 X ULN 6. - Creatinine = 1.5 X ULN 6. Female participants of child bearing potential and male participants whose partner is of child bearing potential must be willing to ensure that they or their partner use effective contraception during the study and for 3 months thereafter 7. Participant is willing and able to give informed consent for participation in the study. Exclusion Criteria: 1. Metastatic disease 2. Patients who have had any chemotherapy or radiotherapy prior to entering the study 3. Acute or sub-acute gastrointestinal occlusion 4. Participation in another clinical trial, with any investigational agent within 30 days prior the study screening 5. Other known malignant neoplastic diseases in the patient's medical history with a disease-free interval of less than 5 years (except for previously treated basal cell carcinoma, superficial bladder tumor and in situ carcinoma of the uterine cervix) 6. History of allergic reactions attributed to compounds of similar chemical or biological composition to drugs used in the study 7. Uncontrolled concomitant illness, including but not limited to: ongoing or active infections; congestive heart failure; unstable angina pectoris; cardiac arrhythmia; or psychiatric illness/social situations that would limit compliance to study requirements |
Country | Name | City | State |
---|---|---|---|
Italy | UO Oncologia Medica IRCCS IRST | Meldola | FC |
Italy | Oncologia Medica PO RAVENNA; FAENZA; LUGO | Ravenna | RA |
Lead Sponsor | Collaborator |
---|---|
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori |
Italy,
Passardi A, Rapposelli IG, Scarpi E, Neri E, Parisi E, Ghigi G, Ercolani G, Avanzolini A, Cavaliere D, Rudnas B, Valgiusti M, Barone D, Ferroni F, Frassineti GL, Romeo A. Neoadjuvant treatment (FOLFOX4 plus hypofractionated tomotherapy) for patients with — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Toxicity events | 6 evaluable patients are needed to assess toxicity. If one toxicity resulting in discontinuation of treatment will be observed in 6 patients, we can conclude that the true probability of toxicity is less than 45% with a confidence >90% and the treatment can be considered safe. If 2 or more toxicity resulting in discontinuation of treatment on 6 patients we can conclude that the true probability of toxicity is greater than 10% with a confidence >90%, and the study will be stopped because not safe and another type of radiotherapy schedule must be designed. | 15 months | |
Primary | The Simon optimal two-stage design (Richard Simon, Controlled Clinical Trials 1989) | It's a two-stage design that use for P1(the proportion of pCR with the new radio-chemotherapeutic treatment) - P0 (the expected proportion of pCR) =0.15. It's used to understand if a treatment is active or not. | 15 months | |
Primary | Complete pathological response (pCR) | According to pathological response criteria, a total regression is considered a complete response. This parameter is used to understand if a treatment is active or not ( if at least 7 patients out of 50 enrolled will achieve a pCR, the treatment could be considered active). | 3 years | |
Secondary | Objective tumor response rate (ORR) | It is the proportion of the intention-to-treat (ITT) population showing a complete or partial response, if confirmed = 4 weeks later.
It will be assessed using RECIST (Response Evaluation Criteria in Solid Tumors) criteria. |
5 years | |
Secondary | Pathological Downstaging Rate | The proportion of subjects with an improved histopathological response by one or more grade relative to baseline following rectal surgery with Total Mesorectal Excision (TME). | 5 years | |
Secondary | Disease-free survival time (DFS) | The time from enrolment date to date of first observed progression, relapse or death. | 5 years | |
Secondary | Overall survival time (OS) | Time from enrolment to the date of death. | 5 years | |
Secondary | Intention-to-treat (ITT) population | The population of all enrolled patients with baseline assessment of disease, receiving 2 cycles of treatment of FOLFOX4 and at least 1 day of radiotherapy. | 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT01227239 -
Preoperative S-1/OHP With Radiation Therapy for Low-lying Rectal Carcinoma in Neo-adjuvant Setting
|
Phase 1/Phase 2 | |
Recruiting |
NCT01459328 -
Resource-Sparing Curative Treatment for Rectal Cancer
|
Phase 3 | |
Recruiting |
NCT04078828 -
PR in Endoscopic LAR for Rectal Cancer
|
N/A | |
Not yet recruiting |
NCT06424522 -
A Bowel Management Program (Retrograde Rectal Enema) for the Treatment of Low Anterior Resection Syndrome in Rectal Cancer Patients
|
Early Phase 1 | |
Terminated |
NCT02797405 -
Tumour and HEalthy Tissues DOse-response and Radiosensitivity Assay
|
N/A | |
Completed |
NCT01751516 -
PET/MRI as a Predictor of Response to Pre-op Chemoradiation in Resectable Rectal Cancer: a Pilot Study
|
||
Terminated |
NCT01111292 -
Inositol in Preventing Colorectal Cancer in Patients With Colitis-Associated Dysplasia
|
Phase 1/Phase 2 | |
Completed |
NCT00682786 -
Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma
|
Phase 2 | |
Recruiting |
NCT04749108 -
Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT01696981 -
Screening for Colorectal Cancer in Older Patients (PLCO Screening Trial)
|
N/A | |
Active, not recruiting |
NCT01899547 -
Laparoscopy-Assisted Surgery for Carcinoma of the Low Rectum
|
N/A | |
Completed |
NCT01333709 -
Multicenter Phase 2 Trial: a Tailored Strategy for Locally Advanced Rectal Carcinoma
|
Phase 2 | |
Recruiting |
NCT04848311 -
Indocanine Green as Tracer for Lymph Nodes Dissection in Station 253
|
N/A | |
Not yet recruiting |
NCT02770911 -
Laparoscopic Anterior Resection With or Without "Dog Ear" Double-stapled Anastomosis for Rectal Cancer
|
Phase 3 | |
Active, not recruiting |
NCT02432963 -
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
|
Phase 1 | |
Active, not recruiting |
NCT04505553 -
Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer
|
Phase 2 | |
Completed |
NCT01372007 -
Influence of Somatuline Autogel 120mg on Post-operative Drainage After Total Mesorectum Excision for Rectumcarcinoma
|
Phase 3 | |
Active, not recruiting |
NCT02817126 -
Robot-assisted Versus Laparoscopic Surgery for Mid/Low Rectal Cancer
|
N/A | |
Completed |
NCT02551237 -
Neoadjuvant Treatment for Advanced Rectal Carcinoma
|
Phase 3 | |
Active, not recruiting |
NCT04713618 -
Changes in Pelvic Health, Sexual Function, and Quality of Life in Women With Pelvic Cancer Undergoing Radiation Therapy
|